Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Depression in Parkinson's disease--Part 2: Therapy and management].
Storch A, Schneider C, Ebersbach G, Fuchs G, Jost WH, Odin P, Reifschneider G, Bauer M. Storch A, et al. Among authors: reifschneider g. Fortschr Neurol Psychiatr. 2010 Aug;78(8):456-67. doi: 10.1055/s-0029-1245535. Epub 2010 Aug 6. Fortschr Neurol Psychiatr. 2010. PMID: 20694938 Review. German.
Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies.
Rascol O, Tönges L, deVries T, Jaros M, Quartel A, Jacobs D; ALLAY-LID I and ALLAY-LID II study groups. Rascol O, et al. Parkinsonism Relat Disord. 2022 Mar;96:65-73. doi: 10.1016/j.parkreldis.2022.01.022. Epub 2022 Feb 8. Parkinsonism Relat Disord. 2022. PMID: 35227940 Free article. Clinical Trial.
Health care situation of patients with relapsing-remitting multiple sclerosis receiving immunomodulatory therapy: a retrospective survey of more than 9000 German patients with MS.
Mäurer M, Dachsel R, Domke S, Ries S, Reifschneider G, Friedrich A, Knorn P, Landefeld H, Niemczyk G, Schicklmaier P, Wernsdörfer C, Windhagen S, Albrecht H, Schwab S; TYPIC Study Investigators. Mäurer M, et al. Among authors: reifschneider g. Eur J Neurol. 2011 Aug;18(8):1036-45. doi: 10.1111/j.1468-1331.2010.03313.x. Epub 2010 Dec 29. Eur J Neurol. 2011. PMID: 21199183
Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis.
Putzki N, Fischer J, Gottwald K, Reifschneider G, Ries S, Siever A, Hoffmann F, Käfferlein W, Kausch U, Liedtke M, Kirchmeier J, Gmünd S, Richter A, Schicklmaier P, Niemczyk G, Wernsdörfer C, Hartung HP; "Mensch im Mittelpunkt" Study Group. Putzki N, et al. Among authors: reifschneider g. Eur J Neurol. 2009 Jun;16(6):713-20. doi: 10.1111/j.1468-1331.2009.02572.x. Eur J Neurol. 2009. PMID: 19475754 Clinical Trial.
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Foley JF, et al. Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25. Lancet Neurol. 2022. PMID: 35483387 Clinical Trial.
36 results